These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 14571495)

  • 1. Beauty's only skin deep: surface technologies emerge in stenting.
    Schwartz RS
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):408-9. PubMed ID: 14571495
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits.
    Wieneke H; Dirsch O; Sawitowski T; Gu YL; Brauer H; Dahmen U; Fischer A; Wnendt S; Erbel R
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):399-407. PubMed ID: 14571494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial stents as a therapeutic platform.
    Roitberg B
    Surg Neurol; 2003 Mar; 59(3):146-7. PubMed ID: 12693402
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries.
    Waksman R; Pakala R; Baffour R; Hellinga D; Seabron R; Kolodgie F; Virmani R
    Cardiovasc Revasc Med; 2006; 7(3):179-84. PubMed ID: 16945826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis.
    Lee BH; Nam HY; Kwon T; Kim SJ; Kwon GY; Jeon HJ; Lim HJ; Lee WK; Park JS; Ko JY; Kim DJ
    Nephrol Dial Transplant; 2006 Sep; 21(9):2432-8. PubMed ID: 16554328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model.
    Huang Y; Salu K; Wang L; Liu X; Li S; Lorenz G; Wnendt S; Verbeken E; Bosmans J; Van de Werf F; De Scheerder I
    J Invasive Cardiol; 2005 Mar; 17(3):142-8. PubMed ID: 15867441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmable elution profile coating for drug eluting stents.
    Al-Lamee K
    Med Device Technol; 2005 Mar; 16(2):12-5. PubMed ID: 15828493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carotid artery in-stent restenosis resolved with drug-eluting stenting.
    Iancu A; Lazar A
    J Invasive Cardiol; 2007 Jul; 19(7):315. PubMed ID: 17620678
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebral embolic protection devices and percutaneous carotid artery stenting.
    Gruberg L; Beyar R
    Int J Cardiovasc Intervent; 2005; 7(3):117-21. PubMed ID: 16243731
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhanced intimal thickening of expanded polytetrafluoroethylene grafts coated with fibrin or fibrin-releasing vascular endothelial growth factor in the pig carotid artery interposition model.
    Walpoth BH; Zammaretti P; Cikirikcioglu M; Khabiri E; Djebaili MK; Pache JC; Tille JC; Aggoun Y; Morel D; Kalangos A; Hubbell JA; Zisch AH
    J Thorac Cardiovasc Surg; 2007 May; 133(5):1163-70. PubMed ID: 17467424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model.
    Collingwood R; Gibson L; Sedlik S; Virmani R; Carter AJ
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):227-32. PubMed ID: 15900559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stents wars.
    Kremastinos D
    Hellenic J Cardiol; 2007; 48(6):387. PubMed ID: 18196665
    [No Abstract]   [Full Text] [Related]  

  • 14. Carotid artery stenting: update.
    Dieter RS; Laird JR
    Int J Cardiovasc Intervent; 2005; 7(3):126-33. PubMed ID: 16243733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabrication of drug-eluting covered stents with micropores and differential coating of heparin and FK506.
    Nakayama Y; Nishi S; Ishibashi-Ueda H
    Cardiovasc Radiat Med; 2003; 4(2):77-82. PubMed ID: 14581087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization.
    Liuzzo JP; Ambrose JA; Coppola JT
    J Invasive Cardiol; 2005 Sep; 17(9):497-502. PubMed ID: 16145242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intimal hyperplasia: the nemesis of cardiovascular intervention.
    Waltham M; Harris J
    ANZ J Surg; 2004 Sep; 74(9):719-20. PubMed ID: 15379792
    [No Abstract]   [Full Text] [Related]  

  • 18. Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia.
    Swanson N; Hogrefe K; Javed Q; Malik N; Gershlick AH
    J Invasive Cardiol; 2003 Dec; 15(12):688-92. PubMed ID: 14660819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hath David once again slayed Goliath?
    Schainfeld RM
    Catheter Cardiovasc Interv; 2004 May; 62(1):69-70. PubMed ID: 15103607
    [No Abstract]   [Full Text] [Related]  

  • 20. Neointimal formation following drug-eluting stents: physiology, timeline, and the influence of drug delivery systems.
    Young JJ
    Rev Cardiovasc Med; 2007; 8 Suppl 1():S3-10. PubMed ID: 17401309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.